advisorsecurities master

ELTXElicio Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key
14738
Ticker
ELTX
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2023-06-02
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
ELTX

Detail

Enriched 2026-08-14 20:47

Market cap
$80,369,198.64
Shares outstanding (class)
19,086,081
Shares outstanding (weighted)
26,264,444
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
33
Location
BOSTON, MA
Description

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data